Trial Profile
A Positron Emission Tomography (PET) Study to Evaluate 18FML10 as an Imaging Agent for Tumour Apoptosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Fluorine-18 ML 10 (Primary)
- Indications Breast cancer; Non-Hodgkin's lymphoma; Ovarian cancer; Small cell lung cancer
- Focus Diagnostic use
- Sponsors GlaxoSmithKline; GSK
- 05 Jun 2015 Status changed from completed to discontinued, as reported by ClinicalTrials.gov record.
- 07 Apr 2014 New trial record